MedTrace Logo

Analysing the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke

NCT04813445 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2022-02-18

No results posted yet for this study

Summary

The main purpose of this trial is to analyse the Effects of Xingnaojing for Mild-to-severe Acute Ischemic Stroke by Metabonomics, proteomics and clinical parameters.

Conditions

Interventions

DRUG

Xingnaojing injection

Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

Sponsors & Collaborators

  • Affiliated Hospital of Nantong University

    collaborator OTHER

  • Nanjing Brian Hospital

    collaborator OTHER

  • Affiliated Hospital of Chengde Medical University

    collaborator OTHER

  • Dongzhimen Hospital, Beijing

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-28
Primary Completion
2022-06-28
Completion
2022-09-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04813445 on ClinicalTrials.gov